See up to 3 months of ACON. The 7-day demo opens the 1M and 3M ranges and puts ACON on your watchlist.
Start 7-day demoLatest ACON insider trades
- Amanda Mae Sequira - DirectorOpen-market purchase$16K
Gregory A. Gould
About Aclarion, Inc. (ACON)
Aclarion, Inc. files with the SEC under CIK 0001635077 and is classified as medical laboratories. It is grouped with Health Care companies on this site.
ACON Form 4 activity by transaction type, last 90 days
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market purchase | 6 | 51,863 | $126K |
ACON insider transactions (Form 4)
2121 Form 4 filings on record, the earliest from Sep 2, 2025, newest first.
| Traded | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Amanda Mae Sequira - Director | Open-market purchase | Common Stock | 5,857 footnote F1 | $2.73 | $16K | |
| ||||||
| Gregory A. Gould - Officer | Open-market purchase | Common Stock | 10,000 footnote F1 | $2.45 | $25K | |
| ||||||
 Ryan Bond - Director | Open-market purchase | Common Stock | 21,122 footnote F1 | $2.37 | $50K | |
| ||||||
| William Wesemann - Director | Open-market purchase | Common Stock | 2,150 footnote F1 | $2.34 | $5K | |
| ||||||
| David K. Neal - Director | Open-market purchase | Common Stock | 7,500 footnote F1 | $2.40 | $18K | |
| ||||||
 Brent Ness - Officer | Open-market purchase | Common Stock | 5,234 footnote F1 | $2.31 | $12K | |
| ||||||
| Ryan Bond - Officer | Grant or award | Common Stock | 55,000 footnote F1,F2 | $0.00 | - | |
| ||||||
| Amanda Mae Sequira - Director | Grant or award | Common Stock | 20,000 footnote F1,F2 | $0.00 | - | |
| ||||||
| Scott Breidbart - Director | Grant or award | Common Stock | 20,000 footnote F1,F2 | $0.00 | - | |
| ||||||
| Gregory A. Gould - Officer | Grant or award | Common Stock | 50,000 footnote F1,F2 | $0.00 | - | |
| ||||||
| Brent Ness - Officer | Grant or award | Common Stock | 100,000 footnote F1,F2 | $0.00 | - | |
| ||||||
| William Wesemann - Director | Grant or award | Common Stock | 20,000 footnote F1,F2 | $0.00 | - | |
| ||||||
| Jeffrey John Thramann - Officer | Grant or award | Common Stock | 100,000 footnote F1,F2 | $0.00 | - | |
| ||||||
| David K. Neal - Director | Grant or award | Common Stock | 20,000 footnote F1,F2 | $0.00 | - | |
| ||||||
| Stephen Deitsch - Director | Grant or award | Common Stock | 20,000 footnote F1,F2 | $0.00 | - | |
| ||||||
| Scott Breidbart - Director | Open-market purchase | Common Stock | 5,664 footnote F1 | $3.18 | $18K | |
| ||||||
| David K. Neal - Director | Open-market purchase | Common Stock | 2,500 | $3.10 | $8K | |
| Brent Ness - Officer | Open-market purchase | Common Stock | 6,289 footnote F1 | $3.18 | $20K | |
| ||||||
| William Wesemann - Director | Open-market purchase | Common Stock | 1,562 footnote F1 | $3.30 | $5K | |
| ||||||
| Brent Ness - Officer | Open-market purchase | Common Stock | 10 footnote F1 | $6.20 | $62 | |
| ||||||
| Gregory A. Gould - Officer | Grant or award | Stock Option (right to buy) | 17,000 | $0.00 | - | |
Item 5.07
Item 8.01, 9.01
Item 1.01, 3.03, 5.03, 8.01, 9.01
ACON insider trading FAQ
What is the latest insider trade for ACON?
Aclarion, Inc. (ACON) had 6 insider filings in the last 90 days, with the most recent on 19 August 2026. The full record for ACON runs to 21 Form 4 filings, the earliest from 2 September 2025. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
How many insiders are buying ACON stock?
6 insider purchases of ACON were filed in the last 90 days, totaling $126K.
How many insiders are selling ACON stock?
No insider sales of ACON were filed in the last 90 days.
Where can I see ACON SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page collects ACON Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Health Care companies with insider activity
Recent insider filings
10The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.
- - Amanda Mae Sequira view on EDGAR
- - Gregory A. Gould view on EDGAR
- - Ryan Bond view on EDGAR
- - William Wesemann view on EDGAR
- - David K. Neal view on EDGAR
- - Brent Ness view on EDGAR
- - Ryan Bond view on EDGAR
- - Amanda Mae Sequira view on EDGAR
- - Scott Breidbart view on EDGAR
Related companies with recent insider activity
Learn more
- How to read insider buying signals
- What an open-market purchase by an insider can and cannot tell you.
- Insider activity in Health Care
- Where ACON's peers are being bought and sold.
- Every recent Form 4
- The market-wide feed, updated as filings arrive from SEC EDGAR.
Follow ACON with a 7-day demo
- ACON on your watchlist
- Every ACON Form 4 filing on record
- Up to 3 months of ACON price history
- The daily trading plan of ranked insider buys, on a delay, with the plan archive
Start 7-day demoCard required. Your card is never charged for the demo.
